Medical Condition News

RSS

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

A community-based health promotion program delivered by over 500 peer volunteers significantly reduces heart disease and stroke in seniors, Canadian Stroke Network researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress today.

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

Long sleep duration is associated with an elevated prevalence of metabolic syndrome in older adults, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Greatbatch, Inc. is proud to join the medical community in celebrating the 50th anniversary of the first successful implantation of the human cardiac pacemaker in the United States. The pacemaker was designed, developed and implanted by Wilson Greatbatch in conjunction with William M. Chardack, M.D. and Andrew A. Gage, M.D.

8 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

Older veterans with PTSD more likely to develop dementia: Report

Older veterans with post-traumatic stress disorder appear more likely to develop dementia over a seven-year period than those without PTSD, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque and first author of the abstract, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)," (Abstract #10004) presented in an oral session today updated positive data from PICASSO.

8 Jun 2010

Excessive sleepiness more common in the U.S. than in Europe: Research

Excessive sleepiness is more common in the U.S. than in Europe, which raises concerns for public health and safety, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

SHS exposure associated with psychological distress, risk of future psychiatric illness: UCL research

Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.

8 Jun 2010

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Family members can help reduce an aging relative's risk of cancer by encouraging healthy lifestyle changes, according to experts at The University of Texas MD Anderson Cancer Center.

8 Jun 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company's IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology being held in Chicago, IL.

8 Jun 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex, Inc. announced today that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity® excimer laser in the treatment of generalized psoriasis when used in combination with Clobex® spray. Dr. Koo is Professor and Vice Chairman in the Department of Dermatology at the University of California San Francisco Medical Center. Spearheading the study will be Dr. Koo's colleague, Tina Bhutani, MD.

8 Jun 2010

Erlotinib can reduce lung cancer death by 26% : Study

Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).

8 Jun 2010

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Celgene International Sàrl today announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology.

8 Jun 2010

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

8 Jun 2010

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

Although plants and animals are very different organisms, they share a surprising number of biological mechanisms. A plant biologist at Tel Aviv University says that one of these mechanisms may be the answer for turning off cancer growth in humans.

8 Jun 2010

Medical Condition News

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Older veterans with PTSD more likely to develop dementia: Report

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

Excessive sleepiness more common in the U.S. than in Europe: Research

SHS exposure associated with psychological distress, risk of future psychiatric illness: UCL research

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

First clinical data for ImmunoGen's IMGN388 anticancer compound presented at ASCO Annual Meeting

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

Erlotinib can reduce lung cancer death by 26% : Study

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News